

Imported food risk statement

Supplementary sports foods and higenamine

Scope: Supplementary sports foods, including liquid forms, powders, and other solid forms

Recommendation and rationale
Does higenamine in imported supplementary sports foods (sports supplements) present a potential medium or high risk to public health:
☑ Yes
\square No
Rationale:

- Higenamine is a potent β2-adrenergic agonist that inhibits constriction of airways and dilates blood vessels in muscles. It may have adverse effects on heart rate and blood pressure, and has the potential to interfere with blood clotting and with metabolism of prescribed drugs.
- Higenamine has no history of safe use as a food in Australia. Higenamine has not been tested adequately for safety in animal studies or humans, particularly with regard to oral exposure.
- Consumption of a small amount of higenamine is likely to result in a urinary higenamine concentration that exceeds the level permitted by the World Anti-Doping Agency (WADA), which indicates that higenamine is bioavailable by the oral route.

General description

Nature of the microorganism/analyte/toxin:

Higenamine is being added as an ingredient to some sports supplements marketed as stimulants or 'fat burners'. It may be listed as an ingredient under a number of synonyms, such as norcoclaurine.

Higenamine is an alkaloid produced by a variety of plants, including edible and toxic species, but none of the plants are typically consumed in Australia.

Extracts from plants are likely to be mixtures of the pharmacologically active *S*-enantiomer and the inactive *L*-enantiomer whereas higenamine synthesized in a laboratory may be primarily *S*-enantiomer. Synthesized higenamine may therefore be more potent, and more hazardous to consume, than higenamine extracted from plants.

Administered parenterally, higenamine increases heart rate and force of contraction of the heart, reduces constriction of major airways, and causes dilation of blood vessels¹. It also inhibits platelet aggregation² which is a critical step in normal blood coagulation.

Adverse health effects:

Higenamine is a potent β 2-adrenergic agonist that has been shown to cause nausea, dizziness³, insomnia⁴, racing heart-rate, and sudden changes in blood pressure⁵ in studies in which it was administered parenterally. These effects are consistent with its pharmacology.

Higenamine inhibits platelet aggregation² and might pose risk of haemorrhage in people with haemophilia, people taking anticoagulant medications, and people who require surgery.

Higenamine inhibits some liver enzymes⁶ and might alter metabolism of prescribed medications.

The thresholds for these adverse effects following oral exposure cannot be determined from the available literature.

General description

Consumption patterns:

In a survey completed in 2018, the Australian Sports Drug Testing Laboratory⁷ found higenamine in 10% of randomly selected "pre-workout" or "fat burner" supplements.

Risk factors and risk mitigation

Consumption of higenamine is of greatest risk to people with pre-existing disorders of heart rate or blood pressure, and may also increase risk of haemorrhage in people with clotting disorders, who are taking anticoagulant medications, or are scheduled for surgery.

When higenamine is listed on the label of a sports supplement, it should be assumed that all higenamine present is the active S-enantiomer.

Higenamine is frequently included in sports supplements in association with other substances that affect blood pressure, such as caffeine. The effects of such combinations are unknown.

Surveillance information:

There is a lack of quantitative surveillance information on the use of higenamine.

Illness associated with consumption of supplementary sports foods formulated to contain higenamine

A search of the scientific literature via EBSCO, PubMed and Google Scholar to February 2020 identified that there has been one case reported of acute breakdown of skeletal muscle that was possibly associated with higenamine⁸.

Data on the prevalence of higenamine in supplementary sports foods

Supplementary sports foods that contain higenamine may not specify the concentration of higenamine on the label, and the claimed concentration may not be accurate⁹. A study that analysed dietary supplements for sale in the USA that listed higenamine or norcoclaurine on the label found evidence of inaccurate labelling. Of the twenty four products analysed, only five made specific claims concerning the amount of higenamine present, but none were accurately labelled and the actual amount was up to 200% the amount stated.

Standards or guidelines

Higenamine does not have a history of safe use as a food in Australia. It is not explicitly permitted as a novel food in the Australia New Zealand Food Standards Code.

Higenamine is not scheduled by the Therapeutic Goods Administration, and is banned for use in competitive sports by the World Anti-Doping Agency¹⁰.

Management approaches used by overseas countries

Higenamine was included on the FDA Dietary Supplement Ingredient Advisory List from the List's inception in April 2019, as an ingredient that does not appear to be lawful in dietary supplements. In October 2021 the FDA reclassified higenamine as a new dietary ingredient (NDI) for which an NDI application is required however one has not been submitted to date¹¹.

This risk statement was compiled in: July 2020, updated December 2021

References

- 1. Zhang N, Lian Z, Peng X, Li Z and Zhu H (2017). Applications of higenamine in pharmacology and medicine. Journal of Ethnopharmacology 196: 242-252
- 2. Yun-Choi HS, Pyo MK, Park KM, Chang KC and Lee DH (2001). Anti-thrombotic effects of higenamine. Planta Medica 67: 619-622
- 3. Feng S, Jiang J, Hu P, Zhang J-Y, Liu T Zhao Q and Li B-I (2012). A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects. Acta Pharmacologica Sinica 33: 2353-1358

- 4. Bloomer RJ, Schriefer JM and Gunnels TA (2015). Clinical safety assessment of oral higenamine supplementation in healthy, young men. Human and Experimental Toxicology 34(10): 935-945
- 5. Bao Y-X, Yu G-R, Xu J-M, Xu Y-Q, Bian Y–T and Zheng D-S (1982). Effect of acute higenamine administration on bradyarrhythmias and His bundle. Chinese Medical Journal 95(10): 781-784
- 6. Liu Y and Santillo MF (2015). Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. Drug Testing and Analysis 8: 307-310
- 7. National Measurement Institute (2018) Survey of Sports Supplements. Australian Sports Drug Testing Laboratory.
- 8. Jeter J, DeZee KJ and Kennedy L (2015). A case of paraspinal muscle rhabdomyolysis in a 22-year-old male after ingesting a supplement containing higenamine. Military Medicine 180 7:e847
- Cohen PA, Travis JC, Keizers PHJ, Boyer FE and Venhuis BJ (2018). The stimulant higenamine in weight loss and sports supplements. Clinical Toxicology DOI: 10.1080/15563650.2018.1497171
- 10. World Anti-Doping Code International Standard Prohibited List 2020 https://www.wada-ama.org/sites/default/files/wada-2020-english-prohibited-list-0.pdf (accessed July 2020)
- 11. US FDA dietary supplement list https://www.fda.gov/food/dietary-supplement-products-ingredients/dietary-supplement-ingredient